Gastromotil for bloating eructation flatulence and nausea and vomiting

GASTROMOTIL
 
4.75/5 ( 95% )
based on 4 ratings

Gastromotil®

Composition:

Each dosage unit contains:   F.C. Tablet     Suspension  (5ml)      Suppository
Domperidone                              10 mg                      5mg                     10,30,60 mg     

Excipients:

F.C. Tablets: Lactose monohydrate, mtcrccrystantne cellulose, pre-gelatinized starch, hydrogenated castor oil, maize starch, povidone k 25, sodium lauryl sulphate,
magnesium stearate, hydroxypropyl methylcellulose, titanium dioxide, polyethylene glycol 6000, polyethyiene glycol 35000.
Suspension: Microcrystalline cellulose, sorbitol 70% solution, methyl paraben,
propylparaben, polysorbate 80, sodium hydroxide, purified water.
Suppositories: Hard fat, butylated hydroxyanlsole, tartaric acid, aerosol 200, polysorbate 80, purified water.

Properties:

Gastromotll® (domperldone) is a dopamine antagonist, which has both prokmenc and antlemerlc properties. It selectively blocks peripheral dopamine receptors in the
gastrointestinal wall, thus enhancing oormal synchronized qastrotntesnnat peristalsis and motility In the proximal portion of the qasrrotnresnnal tract without affecting gastric, biliary or pancreatic secretion. Also, the resHng tone of the gastrooesophageal sphincter Is increased and the pyloric sphincter is relaxed. Gastromotil<l> anttemenc action is due to its direct blocking effect on dopamine receptcrs In the chemoreceptor trigger zone. GastromoUI® does not cross the blood-brain barrier to any appreciable degree and so exerts relatively llttle effect on cerebral dopamlnerglc receptors.

Pharmacokinetics:

Domperidone is repidly absorbed from the gastrointestinal tract with alow bioavailability of about 15 % in fasting subjects although it is increased when domperidone is given afterfood. The low bioavallablllty Is due to first-pass metabollsm. The bloavailabiliCy of rectal domperidone Is similar to that after oral doses, although peak plasma concentrations are achieved after about 1 hour for rectal dose, compared with 30 minutes after oral doses. About 90% of domperldone Is bound to plasma proteins and has a terminal el!mination half-life of about 7.5 hours. Dornpendone. is chiefly cleared from the body by extensive metabolism. About 30% of an oral dose ‘.s excreted In urine within 24 hours, almost entirely as metabolltes; the remainder of a dose Is excreted in the faeces over several days, about 10% as unchanged drug. It does not readily cross the blood-brain barrier. Small amounts of
domperidone are distributed Into breast milk.

Indications:

-The dyspeptic symptom complex that Is often associated with delayed gastric emptying, gastro-oesophageal reflux and oesophagitis:
-eptqastrtc sense of fullness, early satiety, feeling of abdominal distension, upper
abdominal pain;
-bloating, eructation, flatulence;
-nausea and vomiting;
-heartburn with or without regurgitations of gastric contents in the mouth
-Nausea and vomiting of functional, organic, infectious or dietetic origin or Induced by radiotherapy or drug therapy. A specific Indication Is nausea and vomiting induced by dopamine agonists, as used In parkinscn’s disease (such as L-dopa and bromocrtpnne)
-lt is given with paracetamol in the symptomatic treatment of migraine.

Dosage and Administration:

I-Chronic dyspepsia (mainly oral administration):
Adults: 10 mg {1 tablet or 10 rnl] 3 times daily, 15-30 minutes before meals and, if
necessary, once more before retiring.
Children: Oral suspension: 2.5 ml per 10 kg body weight, 3 times daily before meals and, if necessary, once more in the evening. When results are not satisfactory, the above dosage may be doubled in adults and in children over 1 year of age.
2- Acute and Subacute conditions (particularly nausea and vomiting):
Adults: Oral: 20 mg (2 tablets or 20 ml) 3 – 4 times daily before meals and before bedtime.
Rectal: 2 to 4 supposilories (GO mg) daily.
Children: Oral: 5 ml per 10 kg body weight, 3-4 times daily before meals and before
bedtime
Rectal: Up to 2 years: 1 suppository (lO mg) 2-4 times dally.
2-4 years: 1 suppository (3D mg) twice dally.
4-6 years: 1 suppository {3D mg)3 times dally.

Older than 6 years: 1 suppository 130 mg) 4 times daily.
3- Migraine: A dose of 20 mg by mouth may be taken up 10 every 4 hours, with paracetamol. as required up 10 a maximum of 4 doses in 24 hours.

Precautions:

– Gastromotilill: is not recommended for chronic nausea and vomlllng or for the routine prophylaxis of postoperative nausea and vomiting.
– Castromotilil): should be used cautiously in patients with hepatic or renal Impairment.
– Use In Infants: Because the metabolic and blood-brain barrier functions are not fully developed during the first months of life, any drug should only be given to infants with great caution and under close medical supervision. Since the typical absence of neurological side effects with Gastromotl1@ is due 10 its poor penetration through the blood-brain barrier, the possible occurrence of such effects cannot be totally excluded in infants under 1 year of age.

Pregnancy and lactation:

Gastromotllill should only be used during the first trimester of pregnancy if thIs is justified by the anticipated therapeutic benefit Up till, now there has been no evidence of any Increase In the risk of malformations in humans. Domperldone concentrations In breast milk are 4 times lower than corresponding plasma
concentrations. It is not known whether this is harmful to the newborn. Therefore nursing is not recommended for mothers who are taking Gastromotll~, unless the expected benefits outweigh any potential risk.

Drug Interactions:

–  Annmuscanntcs and opioid analgesics may antagonize the prokineUc effects of
Gastromotllill.
– Ketoconazole Increases the plasma concentrations of Castromotllill.
– GastromotlJiII may antagonize the hypoprolactinaemlc effect of drugs such as
bromocriptlne.

Contraindications:

– Hypersensitivity to the product.
–  When stimulation of gastric motility might be dangerous as in gastroinlestinal
haemorrhage, mechanical obstruction, perforation or immediately after surgery.
–  Patients with protacnn-releastnq pttuttary tumour (prolactlnoma)

Side Effects:

– Gastromotil«> does not readily cross the btcod-brain barrier and rarely produces central effects such as extrapyramidal reactions or drowsiness but there has been a few reports of dystonic reactions.
– Plasma – prolactin levels may be Increased which may lead to galactorrhoea or
gynaecomasHa.
– Allergic reactions such as rash and urticaria and transient abdominal cramps have been reponed

Storage:

Tablets: Store at temperature not exceeding 3QOC.
Suspension: Store at temperature nor exceeding JOOC.
Suppositories: Store at ternperature 2°·8°C.

How supplied:

Gastromotllill film coated tablets: Blisters of 10 tablets each.
Gastromotllill suspension: Bottles of 200 ml.
GastromotUiIl adult, children, infant suppositories: Box of 5 suppositories.

Produced by :

EGYPTIAN INT. PHARMACEUTICAL INDUSTRIES CO.
E.I. P.I. CO.
lOth OF RAMADAN CITY • INDUSTRIAL AREA ar, P.O. BOX: 149 TENTH, EGYPT

جاستروموتيل لعلاج المغص الريحى وتكرع وانتفاخ البطن والغثيان والقئ

You can leave a response, or trackback from your own site.

Leave a Reply